The present study explored the role of the medial septal region (MS) in experimental neuropathic pain. For the first time, we found that the MS sustains nociceptive behaviors in rodent models of neuropathic pain, especially in the chronic constriction injury (CCI) model and the paclitaxel model of chemotherapy-induced neuropathic pain. For example, inactivation of the MS with intraseptal muscimol (2 μg/μl, 0.5 μl), a GABA mimetic, reversed peripheral hypersensitivity (PH) in the CCI model and induced place preference in a conditioned place preference task, a surrogate measure of spontaneous nociception. The effect of intraseptal muscimol on PH was comparable to that seen with microinjection of the local anesthetic, lidocaine, into rostral ventromedial medulla which is implicated in facilitating experimental chronic nociception. Cellular analysis in the CCI model showed that the MS region sustains nociceptive gain with CCI by facilitating basal nociceptive processing and the amplification of stimulus-evoked neural processing. Indeed, consistent with the idea that excitatory transmission through MS facilitates chronic experimental pain, intraseptal microinjection of antagonists acting at AMPA and NMDA glutamate receptors attenuated CCI-induced PH. We propose that the MS is a central monitor of bodily nociception which sustains molecular plasticity triggered by persistent noxious insult.

This study explored the effects of septal glutamatergic transmission on septal-hippocampal theta activity via intraseptal microinjection of antagonist at AMPA receptors (AMPAR). The current results showed that microinjection of AMPAR antagonist, NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione, 20 μg/μl, 0.5 μl), evoked a decrease in the frequency of theta activity evoked by various means in anesthetized and behaving rat. Theta wave activity was induced on: (a) intraseptal microinjection of carbachol, an agonist at cholinergic receptors, (b) reticular stimulation, (c) exploration in novel open field (OF), and (d) hind paw (HP) injection of the algogen, formalin. The effect on frequency in the formalin test was observed in an early period on injection of formalin, which was novel to the animal, but not in the later more sustained phase of the formalin test. The effect of NBQX, being seen in both anesthetized and behaving animals, suggests that the modulation of theta wave frequency, including in novelty, is a function of AMPAR in MS. The effect of the antagonist on theta power was less apparent, being observed only in anesthetized animals. In addition to theta power and frequency, intraseptal NBQX also attenuated suppression of CA1 population spike (PS) induced by intraseptal carbachol, thus suggesting that septal glutamate neurotransmission is involved in the spectrum of MS-mediated network responses. Indeed, in the context of behavior, formalin injection induced an increase in the level of septal glutamate, while NBQX attenuated nociceptive behaviors. Notably, MS is involved in the modulation of formalin nociception. These findings suggest that AMPA receptors are a key modulator of septal physiological function.

The hippocampus represents a key structure in the integration of emotional processing, learning and memory, and reward-related behaviors. While the ventral subdivision of the hippocampus (vHPC) is involved in processing emotional values of salient stimuli and goal-directed behaviors, the dorsal hippocampus (dHPC) plays a critical role in episodic, spatial, and associative memory. In addition, it has been shown that the dHPC is necessary for context- and cue-associated reward behaviors, including the expression of reward seeking. The nucleus accumbens (NAc), a central structure in the mesolimbic reward pathway, integrates the salience of aversive and rewarding stimuli and its activity is sufficient to drive aversive and appetitive behaviors. Recent evidence has demonstrated that dHPC→Nucleus Accumbens (NAc) pathway is necessary for the expression of a conditioned place preference. However, despite years of groundbreaking research and identification of direct projections from the dHPC to the NAc, the sufficiency for dHPC→NAC inputs to drive reinforcement and reward-associated behavior remains to be determined. Here using a wide range of complementary and cutting-edge techniques including behavior, in-vivo manipulation using optogenetics, chemogenetics, brain clearing, local field potential, and fiber photometry recordings, we demonstrate that activation of excitatory projections from the CA1 subregion of the dHPC (dCA1) is sufficient to drive reinforcing behaviors. In addition, we provide strong evidence that this reinforcing behavior is driven by 1) a direct projection from the dCA1 to the NAc and 2) enhanced glutamatergic signaling within the NAc. Furthermore, we uncovered that while dCA1 stimulation increases the activity of both enkephalin- and dynorphin-containing medium spiny neurons in the NAc, the selective activity of dynorphin-containing neurons is necessary for the expression of this reinforcing behavior. Our findings shed light on a novel pathway governing reinforcement and further extend the role of the dHPC on reward seeking.